What is SBFM's Intrinsic value?

Sunshine Biopharma Inc (SBFM) Intrinsic Value Analysis

Executive Summary

As of June 11, 2026, Sunshine Biopharma Inc's estimated intrinsic value ranges from $0.00 to $0.00 per share, depending on the valuation methodology applied.

Valuation Method Fair Value (USD) Implied Upside/Downside

Is Sunshine Biopharma Inc (SBFM) undervalued or overvalued?

With the current market price at $2.14, the stock appears to be significantly overvalued.

Understanding Intrinsic Value

Intrinsic value represents the "true" worth of a company based on its fundamentals rather than market sentiment. We've employed multiple methodologies to triangulate Sunshine Biopharma Inc's intrinsic value, including:

Weighted Average Cost of Capital (WACC)

The cost of capital is a critical factor in valuation models, representing the required return for investors.

WACC Component Low High
Long-term bond rate 3.9% 4.4%
Equity market risk premium 4.6% 5.6%
Adjusted beta 1.09 1.42
Cost of equity 8.9% 12.8%
Cost of debt 5.0% 5.0%
Tax rate 0.7% 2.3%
Debt/Equity ratio 1 1
After-tax WACC 6.9% 8.8%

Valuation Methods

Key Financial Metrics

Metric Value
Market Capitalization $1M
Enterprise Value $-6M
Trailing P/E 0.00
Forward P/E 0.00
Trailing EV/EBITDA 0.00
Current Dividend Yield 62.96%
Dividend Growth Rate (5Y) 0.00%
Debt-to-Equity Ratio 0.83

Investment Decision Framework

To determine the most reliable intrinsic value estimate, we weigh each valuation method based on:

  1. Forecast Certainty: DCF methods rely on long-term projections, while earnings power value focuses on current normalized earnings
  2. Business Model Alignment: Dividend models are more appropriate for mature companies with established dividend policies
  3. Historical Accuracy: How well each method has predicted fair value historically

Valuation Weight Matrix

Valuation Method Weight Weighted Value
Weighted Average 100% $0.00

Investment Conclusion

Based on our comprehensive valuation analysis, Sunshine Biopharma Inc's intrinsic value is $0.00, which is approximately 100.0% below the current market price of $2.14.

Key investment considerations:

  • Strong projected earnings growth (-16% to 1% margin)
  • Consistent cash flow generation

Given these factors, we believe Sunshine Biopharma Inc is currently significantly overvalued with the potential for long-term appreciation based on the company's growth trajectory and financial strength.